T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330

Preclinical and emerging clinical studies demonstrate that bispecific T-cell engaging (BiTE) antibody constructs can potently lyse targeted tumor cells, but the determinants for their activity remain incompletely understood. Using human acute myeloid leukemia (AML) cell lines engineered to overexpre...

Descripción completa

Detalles Bibliográficos
Autores principales: Laszlo, G S, Gudgeon, C J, Harrington, K H, Walter, R B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558592/
https://www.ncbi.nlm.nih.gov/pubmed/26295610
http://dx.doi.org/10.1038/bcj.2015.68

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558592/
https://www.ncbi.nlm.nih.gov/pubmed/26295610
http://dx.doi.org/10.1038/bcj.2015.68

Ejemplares similares